Since early August, the world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has put on a stellar ...

A new study uses shopping receipts to show how appetite changes from Ozempic and Wegovy affect grocery and restaurant ...

As Novo Nordisk’s weight-loss pill Wegovy (semaglutide) readies for a launch in the United States early January, it will be a ...

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Major stock indexes ended higher for a fourth straight session Tuesday, with the S&P 500 setting a fresh closing record, ...

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

As GLP-1 weight-loss drugs become more common, their effects may be reshaping everyday food choices in ways that extend far beyond individual health. When people in the United States begin using ...

Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become available in January, analysts say.

U.S. regulators this week gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion ...

The Best Weight Loss Supplements for Women This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: The best ...

While patients currently must get weekly injections of the weight loss drug Wegovy, the FDA has now approved a daily pill version of the product. After spending most of his life back and forth from ...